Cohort studycited by the Tayebat archiveabstract only checked★ key study A-INS-10 in-depth review

Higher insulin doses and outcomes

Glucose-lowering with exogenous insulin monotherapy in type 2 diabetes: dose association with all-cause mortality, cardiovascular events and cancer.

Overview

Holden SE et al.. Diabetes Obes Metab 2015 · PMID 25399739 · DOI 10.1111/dom.12412

People on higher insulin doses died more often, but higher doses are needed by sicker, more insulin-resistant people.

Does the study support the specific claim? Partly · Methodological quality: low

Study explained simply

What did the researchers want to find out?: Association of insulin dose with mortality, MACE, cancer
How was the study done?: Retrospective cohort, UK CPRD, time-dependent dose exposure
How many people, animals or samples were studied?: 6,484; Type 2 diabetes progressing to insulin monotherapy from 2000
What was actually found?: Dose-associated increases in death, MACE, cancer.
How large was the observed effect?: aHR 1.54 per IU/kg/day
What do the results mean in everyday life?: High doses mark severe disease; cause unclear.
What are the study's limitations?: Dose reflects insulin resistance and illness; Reverse causation; Residual confounding
What does it say about Elawady's specific claim?: Support (association) for C-INS-05; mixed for C-INS-03.
Do the results apply to Germany and Europe?: UK data.
What can explicitly not be concluded from this study?: That lowering doses would save lives.

Association of insulin dose with mortality, MACE, cancer

Study design: Cohort study – Retrospective cohort, UK CPRD, time-dependent dose exposure
Population: Type 2 diabetes progressing to insulin monotherapy from 2000
Country: UK
Period: 2000 onwards; mean follow-up 3.3 years
Sample size: 6,484
Inclusion and exclusion criteria: As described in the abstract; details not available in abstract.

Results: Deaths 1,110, MACE 342, cancers 382. Per 1-unit increase in IU/kg/day: death aHR 1.54 (1.32-1.78), MACE 1.37 (1.05-1.81), cancer 1.35 (1.04-1.75).
Absolute risks: Unadjusted 61.3 deaths, 26.4 MACE, 24.6 cancers per 1,000 person-years.
Authors' conclusion: Association between increasing insulin dose and mortality, MACE and cancer; limitations of observational studies mean it should be investigated in interventional studies.

1 IU/kg/day is a large dose step (e.g. 80 IU/day for 80 kg).

Support (association) for C-INS-05; mixed for C-INS-03.

UK data.

Hypothesis-generating.

Multidimensional assessment
Multidimensional assessment
Authenticity of the source	verified
Methodological quality	low
Risk of bias	high
Precision of results	moderate
Directness	direct
Reproducibility	not replicated
Consistency with the overall evidence	unknown
Regional transferability	high
Adequacy of the interpretation (by the archive)	partly correct but over-interpreted

None beyond those stated.

Note: according to the archive, the studies were compiled by the archive operators. Whether Dr. Elawady himself cited this study is not established.

What the archive says about the study: Holden (DOM 2015): in 6,484 insulin-monotherapy patients each extra IU/kg/day raised mortality 54%, MACE 37%, and cancer 35%.
A. What was actually studied?: Association of insulin dose with mortality, MACE, cancer
B. What did the authors find?: Dose-associated increases in death, MACE, cancer.
C. What conclusions do the authors themselves draw?: Association between increasing insulin dose and mortality, MACE and cancer; limitations of observational studies mean it should be investigated in interventional studies.
D. What does the archive derive from it?: Used as 'clean dose-response' proof of insulin harm.
E. Is this derivation scientifically justified?: Numbers correct; 'raised' implies causation the authors explicitly did not claim; dose-response in observational data is expected under confounding by severity.
Adequacy of the interpretation (by the archive): partly correct but over-interpreted